IN THE DRITED STATES PATENT AND TRADEMARK OFFICE

In re Patent /	Application of
----------------	----------------

ANDREOLETTI, ET AL.

Atty. Ref.:

620-359

Serial No.: Unassigned

Group:

Unassigned

U.S. National Phase of PCT/EP2003/008926

Examiner:

Unassigned

Filed:

February 4, 2005

For:

HETEROPOLYMERIC COMPOUND COMPRISING A

SCAFFOLD, AN ADJUVANT AND AN ANTIGEN, AND ITS

USE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 February 4, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

\boxtimes	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the me	
	2.(a)	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/0	C
	2 .(b)	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.0	0
	3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.0	00

Best Available Copy

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

\boxtimes	4.	iden each encl in co	A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. A copy of the International Search Report issued in connection with PCT/EP2003/008926 and references cited are attached.				
This p	oaper	is sub	omitted in accordance with:				
\boxtimes	5.	37 C	CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]				
	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and					
		a)	The required Statement made in item 8 below; or				
		b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.				
	7.		OFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) ement and Rule 17(p) fee), but before final fee payment]; and				
		a)	The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and				
		b)	The required Statement is stated in item 8 below.				
	8.	Stat	ement under 37 CFR 1.97(e)				
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or				
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37				

D Rec's CT/PTO 0 4 FEB 2005

CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

By: ______

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000

Facsimile: (703) 816-4100

INFORMATION DISCLOSUR CITATION	620-3 APPLIC ANDF FILING Febru	REOLETTI, ET AL.	371 of PCT/ Unassigned		08926	
CITATION	620-3 APPLIC ANDF FILING Febru	REOLETTI, ET AL.	Unassigned		08926	
	ANDF FILINGT Febru	REOLETTI, ET AL.				
	FILING Febru		ADAIN -			
(Use several sheets if necessary)			GROUP			
		uary 4, 2005	Unassigned			
	U.S	. PATENT DOCUMENTS			<u> </u>	DATE
*EXAMINER INITIAL DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	PRIATE
					<u></u>	
	FORI	EIGN PATENT DOCUMEN	TS			
					TRANSI	
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	11/2000	WIPO				
	08/1991	WIPO				
	04/1995	United Kingdom				
	01/2001	WIPO				
WO 99/35260	07/1999	WIPO				
				-		
OTHER BOOKING	NTC (lee	Indian Author Title Det	Doublin and in	200 54=	Ļ	
Shinya et al Riome	ini) Civi	cluding Author, Title, Date and Pharmacotherapy, Dece	mbor 1999 V	ayes, etc.	<u> </u> 171-48'	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

Kol et al, The Journal of Immunology, January 1, 2000, Vol. 164, No. 1, pp 13-17

Form PTO-FB-A820 (Also PTO-1449)